Topic summary

Melanocortin agonists: mechanism and the documented adverse profile

Compounds › Other compounds needs a source mislabelling research use only custom synthesis

This is a generated summary. It shows the 5 most-liked posts from a topic of 12, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

a.pereiraTL22 Aug 2024#1

Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable.

Melanocortin agonists, and specifically the version of it that the documentation does not cover. The maintained page handles the general case well and stops exactly where my question starts.

Setting out the gap in case it is a gap in the page rather than a gap in what is known.

10 likes 2y

br.wikstromTL210 Sep 2024#4

crossover_entry, post #3: Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it. If anyone has run this properly I would rather read that than my own guess. Go to post

Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.

Not a conclusion. A place to stand while looking for one.

20 likes in reply to #3 23mo

n.ramosTL216 Oct 2024#8

gradient_review, post #5: Answering the melanocortin agonists question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken. Go to post

Building on post #6 rather than restating it.

The question underneath melanocortin agonists is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.

Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.

27 likes in reply to #5 21mo

cannula_driftTL3Regular25 Oct 2024#9

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.

The claim is narrower than it sounds, and deliberately so.

13 likes 21mo

y.ibarraTL29 Nov 2024#11

a.pereira, post #1: Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Melanocortin agonists, and specifically the version of it that the documentation does not cover. The maintained page handles the general case well and stops exactly where my question starts. Setting… Go to post

Confirming post #8 from a second method, which matters more than confirming it from a second person.

Two questions I would want answered before drawing anything from the melanocortin agonists data above: how were the cases selected, and what happened to the ones that dropped out.

23 likes in reply to #1 21mo

Read the full topic (12 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Naming conventions for research peptides and the confusion they cause — one year on Compounds › Other compounds research use only mislabelling needs a source Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. Asking about Naming conventions for research peptides…	+1	5	181	2y
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…	+100	108	1.3k	8mo
Why catalogue breadth is not evidence of anything Compounds › Other compounds research use only needs a source custom synthesis Under review Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. What changes if the standard account of catalogue breadth is wrong?…		2	38k	2d
Reading a supplier's product description as a marketing document Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…	+86	97	62k	8mo
Research-use-only status: what it means legally and practically Compounds › Other compounds research use only custom synthesis needs a source mislabelling Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. Asking about research-use-only status directly, because I…	+72	81	44k	1d

Related topics — sharing the tags needs a source, mislabelling, research use only

Topic	Participants	Replies	Views	Activity
How to research a compound with no human data without deceiving yourself Compounds › Other compounds needs a source mislabelling custom synthesis research use only Solved Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Question about what the published evidence for this compound actually…	+107	119	11k	12mo
Research-use-only status: what it means legally and practically Compounds › Other compounds research use only custom synthesis needs a source mislabelling Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. Asking about research-use-only status directly, because I…	+72	81	44k	1d
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…	+35	39	688	5mo
Tracking a preprint to publication: a worked example Evidence › Preprints preprint risk of bias needs a source Tracking a preprint to publication: a worked example Writing it up because I had to work it out twice and would rather nobody else did. A preprint question rather than a question about the finding in it. The…	+133	147	15k	7mo
Prescription requirements and telehealth models Sourcing › Regulatory FDA compounding research use only MHRA Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did. Proposing that prescription requirements and telehealth models deserves a…	+91	97	5.4k	7mo